Arcutis Biotherapeutics (ARQT) announced the enrollment of the last subject in the INTEGUMENT-INFANT Phase 2 open-label clinical study, which is evaluating the safety and tolerability of investigational once-daily ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. ZORYVE cream is a highly selective and potent topical phosphodiesterase-4 inhibitor formulated to address the unique needs of individuals with atopic dermatitis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
- Arcutis partners with Tori Spelling, Stella McDermott for campaign
- Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
- Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
- Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho